Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
HERA
About the Trial
The Herceptin Adjuvant trial randomized 5,102 women with HER2 positive early breast cancer to trastuzumab for 1 or 2 years or observation after chemotherapy. One year of trastuzumab reduced disease free survival events by 46 percent and death by about a third, one of the largest benefits ever seen in adjuvant breast oncology. The 2 year arm added nothing. Cardiac toxicity was real but manageable. HERA, with the concurrent NSABP B-31 and N9831 trials, transformed HER2 positive disease from the worst to one of the most treatable breast cancer subtypes, a triumph of targeted therapy driven by Dennis Slamon's work linking HER2 amplification to aggressive disease.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...